In the design of new drugs, a critical point is to identify a biological target that allows generating a therapeutic treatment against a certain pathogen . In general, for a biomolecule to be considered as a good pharmacological target, it must meet 3 points: 1) be essential for the survival of the microorganism, in this case indispensable for T. cruzi, 2) the biomolecule must be absent in humans and 3) the structure of the pharmacological target must have druggable sites, that is, cavities or regions in which the drugs can interact, triggering a potential inhibition of their biological activity . In this sense, TR meets the three criteria to be considered a potential pharmacological target in the search for new molecules with therapeutic activity against ChD .